Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Enveric Biosciences, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 14 | 18 | +4 |
| Shares | 1.11M | 1.15M | +33.6K (+3.0%) |
| Value | $3.42M | $2.72M | −$700.0K (−20.5%) |
New holders (7)
Institutions that held Enveric Biosciences, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 88,886 | $212.0K | 0.00% |
| Penserra Capital Management LLC | 26,986 | $52.0K | 0.00% |
| Creative Planning | 17,577 | $42.0K | 0.00% |
| Citadel Advisors LLC | 13,085 | $31.0K | 0.00% |
| Signaturefd, LLC | 7,000 | $17.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 5,134 | $12.0K | 0.00% |
| FMR LLC | 1 | $0 | 0.00% |
Sold out (3)
Institutions that held Enveric Biosciences, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Bank of New York Mellon Corp | 21,021 | $65.0K |
| Schonfeld Strategic Advisors LLC | 20,400 | $62.0K |
| Bank of America Corp | 10 | $0 |